Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Evaluating the use of PET scanning after first-line treatment for follicular lymphoma

Posted by on Nov 14, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the value of PET (positron emission tomography) scanning after first-line (primary) chemoimmunotherapy in patients with previously untreated follicular lymphoma (FL). This study concluded that PET scanning is a better imaging technique than CT (computed tomography) for assessing treatment response in these...

Read More

Evaluating the VR-CAP regimen versus R-CHOP in transplant-ineligible patients with mantle cell lymphoma

Posted by on Nov 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of first-line (primary) treatment with VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone) versus R-CHOP (VR-CAP with vincristine instead of bortezomib) alone in previously untreated patients with mantle cell lymphoma (MCL). This study concluded that VR-CAP was...

Read More

Evaluating rituximab maintenance therapy for elderly patients with follicular lymphoma

Posted by on Oct 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of maintenance therapy with rituximab (Rituxan) in elderly patients with newly diagnosed follicular lymphoma (FL). This study concluded that maintenance rituximab treatment improved survival outcomes in these patients in a real-world setting. Some background Chemoimmunotherapy containing rituximab...

Read More

Evaluating lenalidomide plus everolimus for relapsed or refractory lymphoma

Posted by on Oct 28, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of lenalidomide (Revlimid) plus everolimus (Afinitor) in pretreated patients with relapsed (recurrent) or refractory (does not respond to treatment) lymphoma. This study concluded that this combination was well-tolerated and showed promising effectiveness in these patients. Some...

Read More

Evaluating rituximab plus lenalidomide for advanced stage follicular lymphoma

Posted by on Oct 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) plus lenalidomide (Revlimid) for patients with previously untreated, advanced stage (stage 3 – 4) follicular lymphoma (FL). This study concluded that this regimen was similarly effective as rituximab plus chemotherapy, but had different side effects. Some...

Read More

Evaluating the impact of older age on patient outcomes after allogenic stem cell transplantation for NHL

Posted by on Oct 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the impact of older age on the outcomes of patients with non-Hodgkin’s lymphoma (NHL) who underwent allogeneic stem cell transplantation (alloSCT). This study concluded that alloSCT in patients older than 65 was associated with higher risks. Some background More than 60% of patients with NHL are older than...

Read More

Evaluating mogamulizumab versus vorinostat in patients with T-cell lymphoma

Posted by on Oct 18, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness of mogamulizumab (Poteligeo) versus vorinostat (Zolinza) in patients with previously treated cutaneous (skin) T-cell lymphoma (CTCL). This study concluded that mogamulizumab was well-tolerated and significantly more effective than vorinostat in these patients. Some background CTCL is a rare type of...

Read More

Evaluating Zevalin followed by stem cell transplantation for relapsed or refractory NHL

Posted by on Oct 18, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of ibritumomab tiuxetan (Zevalin) followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) in patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that ibritumomab tiuxetan...

Read More

Evaluating radioimmunotherapy versus rituximab maintenance therapy in follicular lymphoma

Posted by on Oct 5, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the outcomes of radioimmunotherapy versus rituximab (Rituxan) maintenance therapy in patients with follicular lymphoma (FL). This study concluded that radioimmunotherapy shows similar survival outcomes compared to rituximab maintenance therapy in patients with FL. Some background In patients with FL, rituximab...

Read More

Long-term outcomes of radioimmunotherapy in patients with follicular lymphoma

Posted by on Oct 5, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term outcomes of radioimmunotherapy following first-line (primary) R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with advanced-stage follicular lymphoma (FL). This study concluded that this treatment approach is effective and well-tolerated in...

Read More